Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Hongbeom Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1595-0135; OpenAlex author ID A5067818633, A5109403120. Sources: OpenAlex.

Their work

Papers
53 (first author 4, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 6 papers · 2021: 10 papers · 2022: 7 papers · 2023: 12 papers · 2024: 1 paper · 2025: 9 papers · 2026: 4 papers

Papers 50 of 53

  1. Familial Pancreatic Cancer at a Tertiary Referral Center: Incidence and Clinical Characteristics in Korea. Last author DOI 10.1002/jhbp.70142↗
  2. Multivisceral resection for pancreatic ductal adenocarcinoma with adjacent organ invasion: a propensity score-matched analysis. Co-author DOI 10.1016/j.gassur.2026.102412↗
  3. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  4. Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future u… Co-author DOI 10.4174/astr.2026.110.2.76↗
  5. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  6. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  7. Synthetic data generation method improves risk prediction model for early tumor recurrence after surgery in patients with pancreatic cancer. Last author DOI 10.1038/s41598-025-15800-4↗
  8. Implications of portal vein/superior mesenteric vein involvement in pancreatic cancer: A comprehensive correlation from preoperative radiological assessment to… Last author DOI 10.1097/js9.0000000000002307↗
  9. The impact of distress at diagnosis in patients with pancreatic cancer undergoing pancreatectomy. Co-author DOI 10.1186/s12885-025-14365-9↗
  10. Prognostic Accuracy of ypTNM Stage in Patients with Pancreatic Cancer in the Era of Modern Neoadjuvant Therapy. Last author DOI 10.1245/s10434-024-16792-7↗
  11. Optimal Number of Lymph Nodes Retrieved to Lower the Risk of False N0 for Patients with Pancreatic Cancer Undergoing Curative Surgery. Last author DOI 10.1245/s10434-025-18029-7↗
  12. Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study. Last author DOI 10.4174/astr.2025.108.4.231↗
  13. Predicting prognosis and optimal timing for surgery using CA 19-9 in patients with pancreatic cancer who underwent FOLFIRINOX-based neoadjuvant therapy: a retr… Last author DOI 10.4174/astr.2025.109.6.348↗
  14. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  15. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  16. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  17. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Co-author DOI 10.1038/s43018-022-00479-7↗
  18. Author Correction: Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtype… Co-author DOI 10.1038/s43018-023-00581-4↗
  19. Prognosis of pancreaticoduodenectomy in octogenarians for pancreatic ductal adenocarcinoma with propensity score matched analysis. Co-author DOI 10.1111/ans.18679↗
  20. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  21. Whole exome sequencing and RNA sequencing analyses of PDAC samples Co-author DOI 10.21203/rs.3.pex-2062/v1↗
  22. Mass spectrometry-based proteomic analysis of PDAC samples Co-author DOI 10.21203/rs.3.pex-2063/v1↗
  23. Bioinformatics analysis of PDAC subtypes Co-author DOI 10.21203/rs.3.pex-2064/v1↗
  24. Cell-based assays for potential prognostic biomarkers in PDAC Co-author DOI 10.21203/rs.3.pex-2065/v1↗
  25. Assays for orthotopic PDAC mouse models Co-author DOI 10.21203/rs.3.pex-2066/v1↗
  26. Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/biomedicines11082302↗
  27. The incidence and clinical features of familial pancreatic cancer in Korea. First author DOI 10.1002/jhbp.1117↗
  28. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pan… First author DOI 10.1002/jhbp.845↗
  29. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  30. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohor… Co-author DOI 10.1093/clinchem/hvac153↗
  31. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Co-author DOI 10.3389/fonc.2022.945829↗
  32. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Co-author DOI 10.3390/cancers14092067↗
  33. Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.3390/cancers15010294↗
  34. Pattern of local recurrence after curative resection in pancreatic ductal adenocarcinoma according to the initial location of the tumor. First author DOI 10.1002/jhbp.854↗
  35. Peritumoral lymph nodes in pancreatic cancer revisited; is it truly equivalent to lymph node metastasis? Co-author DOI 10.1002/jhbp.940↗
  36. Diffusion-weighted MR imaging in pancreatic ductal adenocarcinoma: prediction of next-generation sequencing-based tumor cellularity and prognosis after surgica… Co-author DOI 10.1007/s00261-021-03177-7↗
  37. Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion. Co-author DOI 10.1007/s00330-021-07847-4↗
  38. Microbiome Markers of Pancreatic Cancer Based on Bacteria-Derived Extracellular Vesicles Acquired from Blood Samples: A Retrospective Propensity Score Matching… Co-author DOI 10.3390/biology10030219↗
  39. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗
  40. CORRIGENDUM: Addition of data source: Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.4.252↗
  41. Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreati… First author DOI 10.4174/astr.2021.100.6.320↗
  42. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  43. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  44. Is the New T1 Category as Defined in the Eighth Edition of the AJCC Pancreatic Cancer Staging System an Improvement? Co-author DOI 10.1007/s11605-019-04464-x↗
  45. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.07.029↗
  46. Multi-Biomarker Panel Prediction Model for Diagnosis of Pancreatic Cancer: a retrospective and multi-center cohort study Co-author DOI 10.21203/rs.3.rs-76136/v1↗
  47. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Co-author DOI 10.3389/fonc.2020.616440↗
  48. Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061443↗
  49. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Co-author DOI 10.3390/cancers12082036↗
  50. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 36 shared papers, 2017–2026 · strength 4.45
  2. In Woong Han · 18 shared papers, 2020–2026 · strength 3.91
  3. Jin Seok Heo · 20 shared papers, 2020–2026 · strength 3.90
  4. Jin‐Young Jang · 31 shared papers, 2017–2024 · strength 3.78
  5. Sang Hyun Shin · 16 shared papers, 2021–2026 · strength 3.71
  6. So Jeong Yoon · 11 shared papers, 2022–2026 · strength 2.53
  7. Hyeong Seok Kim · 11 shared papers, 2017–2026 · strength 2.31
  8. Hochang Chae · 8 shared papers, 2025–2026 · strength 2.16
  9. Hye Jeong Jeong · 8 shared papers, 2022–2025 · strength 1.78
  10. Taesung Park · 14 shared papers, 2020–2023 · strength 1.53
  11. Yoonhyeong Byun · 13 shared papers, 2019–2023 · strength 1.47
  12. Jae Seung Kang · 11 shared papers, 2019–2023 · strength 1.25
  13. Yoo Jin Choi · 9 shared papers, 2019–2023 · strength 1.07
  14. Chang Moo Kang · 7 shared papers, 2020–2026 · strength 1.05
  15. Daechan Park · 8 shared papers, 2021–2023 · strength 0.97
  16. Ja‐Lok Ku · 8 shared papers, 2019–2023 · strength 0.92
  17. Joo Kyung Park · 7 shared papers, 2020–2025 · strength 0.88
  18. Min‐Sik Kim · 7 shared papers, 2023 · strength 0.83
  19. Sangyeop Hyun · 7 shared papers, 2023 · strength 0.83
  20. Sung Hee Baek · 7 shared papers, 2023 · strength 0.83
  21. Keehoon Jung · 7 shared papers, 2023 · strength 0.83
  22. Sang‐Won Lee · 7 shared papers, 2023 · strength 0.83
  23. Do Young Hyeon · 7 shared papers, 2023 · strength 0.83
  24. Duk Ki Kim · 7 shared papers, 2023 · strength 0.83
  25. Gibeom Kim · 7 shared papers, 2023 · strength 0.83

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.